A patient who had repeated episodes of bradycardia while on cisplatin therapy is described. Cisplatin-induced bradycardia has not been reported previously. Deposition of cisplatin in the sinoatrial-node area might explain this cardiotoxic effect. Drug Intell Clin Pharm 1983; 17: 899–901.
RosenbergBVan CampLKrigastT. Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature1965; 205: 698–9.
2.
DurantJR. Cisplatinum—a clinical overview. In: PrestaykoAWCrookeSTCarterSK, eds. Cisplatinum—current status and new developments. New York: Academic Press, 1980: 317–21.
3.
JacobsC. The role of cisplatinum in the treatment of recurrent head and neck cancer (ibid., 423–40).
4.
Von HoffDElsonD. Cisplatinum in lung cancer (ibid., 445–58).
5.
RosenGNirembergACaparrosBJurgensHTahCGutierrezM. Cisplatinum in metastatic osteogenic sarcoma (ibid., 465–75).
6.
GreenAHayesFAPrattCBEvansWEHowarthCBSenzerN. Phase II evaluation of cisplatinum in children with neuroblastoma and other malignant solid tumors (ibid., 477–84).
7.
Von HoffDSchilskyRReichertC. Toxic effect of cis-dichlorodiammineplatinum (II) in man. Cancer Treat Rep1979; 63: 1527–31.
8.
KrakoffIH. Nephrotoxicity of cis-dichlorodiammineplatinum (II). Cancer Treat Rep1979; 63: 1523–5.
9.
TalleyRWO'BryanRMGuttermanJUBrownleeRWMcCredieKB. Clinical evaluation of toxic effects of cis-diammine dichloroplatinum. (NSC-119875)—phase I clinical study. Cancer Chemother Rep1973; 57: 465–71.
10.
WiltshawECarrB. Cisplatinum (II) diamminedichloride. Clinical experience of the Royal Marsden Hospital and Institute of Cancer Research, London. In: ConnorsTARobertsJJ, eds. Platinum coordination complexes in cancer chemotherapy. Recent results in cancer research, vol 48. Berlin: Springer Verlag, 1974: 178–82.
11.
Von HoffDRozencweigMPiccartM. The cardiotoxicity of anticancer agents. Semin Oncol1982; 9: 23–33.
12.
CortesEPLutmanGWankaJ. Adriamycin cardiotoxicity. A clinicopathologic correlation. Cancer Chemother Rep (part 3) 1975; 6: 215–25.
13.
MinowRABenjaminRSGottliebJA. Adriamycin Cardiomyopathy—an overview with determination of risk factors. Cancer Chemother Rep (part 3) 1975; 6: 195–201.
DascalYPrestaykoAWCrookeST. Morphological manifestations of cisplatinum analogs in rats. In: PrestaykoAWCrookeSTCarterSK, eds. Cisplatinum—current status and development. New York: Academic Press, 1980: 249–69.
18.
ManakaRCWolfW. Radiopharmacokinetics of cisplatinum (ibid., 271–83).
